Calcitriol [1,25-dihydroxyvitamin D 3 ; 1,25(OH) 2 D 3 ] 5 is the metabolite of vitamin D with the highest activity on mineral metabolism. With parathyroid hormone (PTH) and calcitonin, it regulates intestinal calcium absorption and bone remodeling, and it influences growth, differentiation, and function of a broad range of cells (1, 2 ) . The biological actions of 1,25(OH) 2 D 3 are mediated by interaction with its specific nuclear receptor (VDR) in target cells. Through transcriptional or posttranscriptional patterns of activity, the 1,25(OH) 2 D 3 -VDR complex can modulate the effects of vitamin D (3 ) . VDR belongs to the superfamily of steroid receptors, as do thyroid hormone and vitamin A receptors. It has a nearly ubiquitous tissue distribution, including cells of the human hematolymphopoietic tissue (4, 5 ) , where its presence allows 1,25(OH) 2 D 3 to reduce immunologic activity of T and B lymphocytes and to activate monocyte-macrophage functions.
A feature somewhat unique is the positive effect of the ligand calcitriol on both VDR cellular production and VDR activity. Exposure of 3T6 mouse fibroblasts to 1,25(OH) 2 D 3 was found to cause an increase of VDR cellular content, accompanied by phosphorylation of receptors and increase of its mRNA concentrations (1 ) . The up-regulation of VDR cellular production by 1,25(OH) 2 D 3 was found in isolated rat kidneys (6 ) and in intact rats (7 ) , whereas, to our knowledge, no data are available on humans.
Modified production of VDR could occur in primary hypercalciuria, a defect characterized by increased urinary calcium excretion and normal plasma calcium concentrations (8 ) . In genetically hypercalciuric stone-forming rats, the number of VDR molecules was increased in duodenal cells; the increase could be maintained by a posttranscriptional effect of 1,25(OH) 2 D 3 (9 ) . A disorder of vitamin D activity has been hypothesized in human primary hypercalciuria, which could be attributable to increased 1,25(OH) 2 D 3 synthesis or to increased sensitivity of patients' cells to 1,25(OH) 2 D 3 .
Cellular production of VDR could be influenced by VDR gene single-nucleotide polymorphisms (SNPs) at the 3Ј-end region or at the translation starting site. This was suggested by results of in vitro experiments analyzing the functional effect of these SNPs in leukocytes (10 ) or in transfected HeLa or COS-7 cells (11 ) . A SNP at the 3Ј-end region does not cause an amino acid change in VDR protein. However, it could influence VDR activity and, thus, DNA transcription efficiency. A SNP in the translation starting codon leads to a shorter molecule lacking the first three amino acids; this variant could be more efficient in stimulating transcription of vitamin D-dependent proteins (12 ) . Cloning of the human VDR gene has made possible measurement of VDR expression in human tissues and in circulating leukocytes (13 ) .
The aim of the present study was to investigate the in vivo response of human VDR (hVDR) mRNA to 1,25(OH) 2 D 3 in human leukocytes. To measure VDR mRNA, we used the TaqMan fluorescent chemical analysis applied to reverse transcription-PCR (RT-PCR) (14, 15 ) . The dependence on exogenous 1,25(OH) 2 D 3 was evaluated in healthy volunteers after oral administration of 1,25(OH) 2 D 3 . The dependence on endogenous 1,25(OH) 2 D 3 was evaluated in hypercalciuric patients with calcium kidney stones compared with normocalciuric stone-formers. These patients were genotyped for the SNPs at the 3Ј-end region and at the translation starting codon of the VDR gene; their genotypes were related to VDR mRNA production in leukocytes.
Materials and Methods materials
All reagents used for RNA extraction were from BDH, except guanidine, which was from Boehringer-Mannheim. All reagents used for reverse transcription, PCR, and the synthesis of VDR probe and primers were from Applied Biosystems. 1,25(OH) 2 They were required to have produced at least one calcium stone and to have no diseases other than stones. They were not taking medications for stones or other reasons and had normal kidney function, and urinary function had to be normal (plasma creatinine Ͻ12 mg/L and urinary pH Ͻ5.5 at least during one examination). No urinary tract dilatation or obstruction was shown by echographic examination. Hypercalciuria was defined as the excretion of calcium Ͼ7.5 mmol/24 h in males or Ͼ6.25 mmol/24 h in females or Ͼ100 mol/kg of body weight for both genders. Patients were genotyped for VDR gene polymorphisms at the translation start codon and at the 3Ј-end region. Blood samples were collected from patients after a midnight fast. Calcium, creatinine, 1,25(OH) 2 D 3 , and PTH were measured in plasma. Calcium was also measured in 24-h urines. VDR mRNA was measured in leukocytes.
This study was approved by the local research Ethics Committee, and informed consent was obtained from each participant (healthy volunteers and renal-stone formers).
isolation of total rna and cDNA synthesis
We collected 8 mL of blood from healthy donors in tubes containing 15 mL of 4 mol/L guanidine thiocyanate. Five-milliliter aliquots were frozen at Ϫ80°C. A guanidine thiocyanate-based assay was used for the extraction of total RNA (16 ) . We mixed 2 g of RNA with 10ϫ reverse transcription buffer, 5.5 mM MgCl 2 , 500 mM deoxynucleotide triphosphates, 2.5 mM random hexamers, 0.4 U/L RNase inhibitor, and 1.25 U/L MultiScribe Reverse Transcriptase for the reverse transcription procedure. Reverse transcription was performed in three steps: incubation for 10 min at 25°C, reverse transcription for 30 min at 48°C, and reverse transcription inactivation (for protein denaturation) for 5 min at 95°C.
pcr procedure
Real-time quantitative RT-PCR analyses of VDR were performed with an ABI PRISM 7700 Sequence Detection System instrument and software (Applied Biosystems). Oligonucleotide sequences were chosen to span the junction between exons 3 and 4 of VDR cDNA, using the primer design software Primer Express TM (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was chosen as an internal standard to control for variability in amplification. The sequences of primers and probes used are shown in Table 1 . The VDR target probe was labeled at the 5Ј end with the reporter dye molecule 6-carboxyfluorescein (FAM; emission at 538 nm). The GAPDH target probe was labeled with 6-carboxy-4,5-dichloro-2,7-dimethoxyfluorescein (JOE; emission at 546 nm). Both probes were labeled with the quencher fluor 6-carboxytetramethylrhodamine (TAMRA; emission at 582 nm) at the 3Ј end. During the PCR extension cycle, the Taq DNA polymerase cleaves the probes and releases the reporter dye, producing an increase in fluorescent emission monitored in real time by software. Each well is screened for fluorescence every 7 s, and signal is considered positive when the fluorescence intensity exceeds 10 SD of the baseline. This is the threshold cycle (Ct) (17, 18 ) . To obtain PCR conditions with reduced variability, PCR premixes containing all reagents except for target were prepared and aliquoted into optical reaction PCR tubes in a 96-well microtiter plate format (Applied Biosystems). No-template controls, calibrators, and unknown samples were assayed in triplicate. For composition of the PCR mixture, see Table 2 . The PCR was performed in three steps: AmpErase uracil-N-glycosylase activation (2 min at 50°C), AmpliTaq Gold enzyme activation (10 min at 95°C), and 50 cycles PCR (denaturation for 15 s at 95°C and annealing/extension for 1 min at 60°C).
pcr conditions
Potential PCR product contaminants in which dTTP is substituted by dUTP were primarily digested by uracil-N-glycosylase (19 ) . The test for contaminating genomic DNA was performed in triplicate, with 100 ng of extracted total RNA processed similar to other samples on the plate. The Ct values did not reveal any amplification of genomic DNA. PCR conditions were optimized for oligonucleotide and probe concentrations.
genotyping Genomic DNA was isolated from peripheral blood cells by standard procedures. The T/C polymorphism in the first of two start codons (ATG) at the translation initiation site of the VDR gene was detected by restriction fragment length polymorphism analysis using the endonuclease FokI. The PCR reaction was carried out in a total volume of 25 L with the primers 5Ј-AGCTGGCCCTGGCACT-GACTCTGCTCT-3Ј (forward) and 5Ј-ATGGAAACAC-CTTGCTTCTTCTCCCTC-3Ј (reverse) at an annealing temperature of 60°C for 35 cycles. PCR products were digested with FokI at 37°C for 3 h and analyzed by agarose gel electrophoresis. Depending on the digestion pattern, individuals were classified as FF when they were homozygous for the absence of the FokI site, as ff when they were homozygous for the presence of the FokI site, or as Ff in the case of heterozygosity. Digestion of the amplified 265-bp PCR product gave two fragments, of 69 and 196 bp.
Polymorphism of the 3Ј-noncoding sequences lying in the intron between exons 7 and 8 of VDR was detected by restriction fragment length polymorphism analysis using the endonuclease BsmI. The PCR reaction was carried out in a total volume of 25 L with the primers 5Ј-CAAC-CAAGACTACAAGTACCGCGTCAAGTGA-3Ј (forward) and 5Ј-AACCAGCGGGAAGAGGTCAAGGG-3Ј (reverse) at an annealing temperature of 65°C for 35 cycles. PCR products were digested with BsmI at 37°C overnight and analyzed by agarose gel electrophoresis. Depending on the digestion pattern, individuals were classified as BB when homozygous for the absence of the BsmI site, as bb when homozygous for the presence of the BsmI site, or as Bb in the case of heterozygosity. Digestion of the amplified 825-bp PCR product gave two fragments, of 650 and 175 bp, respectively. VDR probe CCT GCC GGC TCA AAC GCT GTG VDR forward primer CTC ATC TGT CAG AAT GAA CTC CTT CA VDR reverse primer TCA CCA AGG ACA ACC GAC G GAPDH probe CCG ACT CTT GCC CTT CGA AAC GAPDH forward primer GAA GGT GAA GGT CGG AGT CA
GAPDH reverse primer
CTT TAG GGT AGT GGT AGA AG 
statistical analysis
Statistical analysis was performed with the Student t-test or one-way ANOVA to evaluate significant differences in the data means. Distribution of qualitative variables (means Ϯ SE) was compared in the different groups by the Fisher exact test or the 2 test. Statistical analyses were conducted at the ␣ ϭ 0.05 level and were two-tailed. All analyses were performed with the SPSS 10 statistical package on a Macintosh G4 computer (Apple Computer).
Results

relative quantification of vdr mRNA
To quantify VDR mRNA in leukocytes, we constructed a calibration curve using GAPDH mRNA as an endogenous control (GAPDH being a "housekeeping" gene). Shown in Fig. 1 are amplification plots of VDR and GAPDH. Serial dilutions of cDNA from 100 ng to 6.4 pg were tested in triplicate to assess the Ct. The ⌬Rn value, used for construction of the amplification plots, is the emission of the reporter over the starting background fluorescence. ⌬Rn was calculated as the difference between Rn ϩ and Rn Ϫ . Rn is the normalized reporter, obtained by dividing the emission intensity of the reporter by the emission intensity of the passive reference; Rn ϩ refers to samples with templates and Rn Ϫ to samples without templates. Calibration curves for VDR and GAPDH mRNA are shown in Fig. 2 , in which the Ct is plotted vs the logarithm of the starting quantity of RNA in pg. The equations for both lines are shown. Leukocyte VDR mRNA is reported as 2
Ϫ⌬⌬Ct . The cell content of VDR mRNA was normalized by use of an endogenous referent, GAPDH mRNA, and a calibrator. A known quantity of VDR mRNA extracted from a human kidney was used as calibrator. The intraand interassay CVs of this method were 1.3% (n ϭ 10) and 1.7% (n ϭ 4), respectively.
effect of 1,25(OH) 2 D 3 on vdr mRNA concentrations in blood leukocytes
Modifications of VDR mRNA concentrations were measured in leukocytes obtained from six healthy individuals 8 h after an oral dose of 1,25(OH) 2 D 3 . Results showed a similar increase in VDR mRNA in all individuals (Fig. 3) . VDR mRNA concentrations increased to 1.6 (0.1)-fold above the value at time of ingestion. Correspondently, 8 h after the administration of 1,25(OH) 2 D 3 , mean (SE) circulating concentrations of 1,25(OH) 2 D 3 were 1.6 (0.3)-fold higher than the concentrations at the time of ingestion (n ϭ 6; R ϭ 0.645), as shown in Fig. 3 . In one individual, this test was repeated on 4 different days; the intrasubject CV was 6.9%. To determine in more detail the kinetics of the VDR mRNA increase, we measured it at different time points in another group of 10 healthy individuals. This experiment confirmed that 1,25(OH) 2 D 3 ingestion induced an increase of VDR mRNA (Fig. 4) . The maximum increase was reached at different times between 1 and 5 h, with a mean (SE) of 3.6 (1.3) h. The maximum increase in VDR mRNA was also quite variable, and ranged from 1.2-to 11.1-fold of the value before 1,25(OH) 2 D 3 consumption.
hypercalciuric and normocalciuric stoneformers
Basal production of VDR mRNA was slightly higher in hypercalciuric than in normocalciuric stone-formers (Table 3). The VDR mRNA concentrations were not related to calcium excretion or to plasma calcium, plasma PTH, or 1,25(OH) 2 D 3 concentrations. Because of the wide range of values, we divided the patients in two groups, using as cutoff the mean value for leukocyte VDR mRNA in all 71 patients [0.410 (0.048) 2 Ϫ⌬⌬Ct ]. Sixteen hypercalciuric patients (43%) and 7 normocalciuric patients (21%) had VDR
Fig. 1. Amplification plots of hVDR (A) and GAPDH (B).
Different dilutions of total RNA from leukocytes were tested in triplicate. Amplification plots were used to determine the Ct. The x axis represents the PCR cycle number, and the y axis represents the mean ⌬Rn value, i.e., the emission of the reporter over the starting background fluorescence.
mRNA above this mean value (Fisher exact test, P ϭ 0.047).
The genotype distribution of the patients is shown in Table 4 . The frequency of patients with high or low VDR mRNA in leukocytes was not related to the patients' genotypes. Similarly, there was no difference between the mean values for VDR mRNA in patients bearing allele variants at the two loci. No relationship was found when normocalciuric and hypercalciuric patients were analyzed separately.
Discussion
In this study we measured the VDR mRNA in leukocytes, applying a single-tube assay for relative measurements (13, 14 ) . Stimulation of leukocyte VDR mRNA production by 1,25(OH) 2 D 3 was tested both in healthy volunteers and in hypercalciuric stone-formers, where a possible increase was investigated. Our findings suggest that VDR mRNA production is stimulated in leukocytes by 1,25(OH) 2 D 3 . No endogenous activation of VDR mRNA production was found in individuals with primary hypercalciuria. The stimulation of VDR mRNA should induce an increase of VDR protein production, even if our findings do not give a direct measurement of the increase.
PCR reactions were performed in the presence of two conventional primers for the amplification of the target molecule (VDR) and of an oligonucleotide probe carrying two fluorescent dyes: FAM at the 5Ј end, serving as a reporter, and the quencher TAMRA at the 3Ј end. During PCR amplification, the Taq DNA polymerase displaces the probe from the template and separates the reporter from the quencher; as a consequence, the fluorescence signal increases. The emitted fluorescence is directly proportional to the number of template molecules in the tube. Each cycle further increases the signal, thereby allowing careful monitoring of the reaction kinetics. With this detection system we obtained highly sensitive and reproducible mRNA quantification, as demonstrated by low intra-and interassay CVs for RT-PCR. Therefore, this method can detect slight differences in mRNA production. Relative quantification is a quite common procedure used to compare differences in mRNA targets among different samples. In this case, RT-PCR was applied to the measurement of temporal variations in the concentrations of mRNA molecules (before and after calcitriol administration) and to differences between two groups (normocalciuric and hypercalciuric stone-formers), both compared with an internal control.
A single oral dose of 1,25(OH) 2 D 3 was shown to stimulate VDR mRNA production in leukocytes with a The VDR gene has been considered a candidate gene for idiopathic hypercalciuria, but no firm association has been found with stone disease or primary hypercalciuria (21 ) . An up-regulation of VDR expression has been observed in enterocytes and bone cells of hypercalciuric rats (9 ). 1,25(OH) 2 D 3 administration gave rise to a further activation of VDR expression via a posttranscriptional mechanism, causing increased sensitivity of bone and enteral cells to 1,25(OH) 2 D 3 and high urinary excretion (9 ) . An increased sensitivity to vitamin D has been hypothesized in humans and could increase VDR expression in all vitamin D-dependent cells, including lymphocytes and macrophages. In the present work we tested these cell lines as a models of VDR expression. Our results show only a slight increase in leukocyte VDR mRNA under baseline conditions and a slight increase in the number of hypercalciuric patients with values above the mean. However, because of the wide range of values both at baseline and after 1,25(OH) 2 D 3 ingestion, our findings do not allow a definite conclusion about the sensitivity to 1,25(OH) 2 D 3 , although we did not observe any increase in 1,25(OH) 2 D 3 plasma concentrations in our patients with primary hypercalciuria (22 ) .
We studied the genotype distribution previously. We found no differences between normocalciuric and hypercalciuric stone-formers for polymorphisms in the starting site and in the 3Ј-end region of the VDR gene (23 ) . Genetic polymorphisms could lead to more efficient VDR activity by stimulating cellular response to vitamin D. This gain of function was suggested either for allele variants of the 3Ј-end region located on intron 9, which cause no amino acid change in the VDR molecule, or for the translation starting codon polymorphism, which would produce a VDR molecule three amino acids shorter. Our findings do not support this hypothesis because we did not observe any increase in VDR mRNA in individuals carrying variant alleles at the VDR locus. However, further experiments in which VDR production is stimulated are needed to confirm these results.
In conclusion, this research provides evidence for the use of leukocytes as a model to study interactions between 1,25(OH) 2 D 3 receptor and 1,25(OH) 2 D 3 or other calciotropic hormones, such as PTH. The technique used is sufficiently sensitive and accurate to assess increases in mRNA concentrations. We also demonstrated for the first time, to our knowledge, that nuclear receptor gene expression is regulated by the ligand in human leukocytes. Finally, we excluded differences in VDR expression under baseline conditions between normocalciuric and hypercalciuric stone-formers and between individuals with different VDR genotypes. 
